SARASOTA, Florida, June 21, 2017 /PRNewswire/ --
International Consolidated Companies, Inc. (INCC) announced today it entered into an exclusive license agreement with CBD Medicinals, LLC for a patent application and trade secrets surrounding the development of an over the counter cannabidiol (CBD) formulation to improve cognitive function in adults.
This technology included novel combinations of CBD, mushroom derived hericenones, and neurotransmitter precursors. Both hericenones and CBD are known to have neuro-protective and neuro-regenerative effects in vivo.
"This will allow us to develop designer CBD products focused on niche markets where the demand is high," said Antonio Uccello, President INCC.
International Consolidated Companies (INCC) was founded in 2002. INCC is focused on acquiring and producing innovative, high quality, and cost-efficient cannabis technologies.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material may contain statements about expected future events and/or financial results that are forward-looking in nature and subject to risk and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements to be materially different from the statements made herein.
SOURCE International Consolidated Companies, Inc.